Health problems most commonly diagnosed among young female patients during visits to general practitioners and gynecologists in France before the initiation of the human papillomavirus vaccination program

2011 ◽  
Vol 21 (3) ◽  
pp. 261-268 ◽  
Author(s):  
Eric Van Ganse ◽  
Laurent Letrilliart ◽  
Hélène Borne ◽  
Francois Morand ◽  
Matthieu Robain ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
General Practitioners ◽  
Health Problems ◽  
Young Female ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
Female Patients

National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 291 ◽  
Author(s):  
Julia M. L. Brotherton ◽  
Julie Leask ◽  
Cath Jackson ◽  
Kirsten McCaffery ◽  
Lyndal J. Trevena
Keyword(s):  
Human Papillomavirus ◽  
General Practitioners ◽  
Hpv Vaccine ◽  
Cervical Screening ◽  
Hpv Vaccination ◽  
Vaccine Safety ◽  
Population Based ◽  
Vaccination Program ◽  
Routine Practice ◽  
Human Papillomavirus Vaccination

Background: Between 2007 and 2009, Australian general practitioners (GPs) were involved in implementing a population-based human papillomavirus (HPV) vaccination program. We investigated GPs’ experiences of delivering the HPV vaccine to women aged 18–26. Methods: We posted a survey to 1000 GPs. The survey was informed by 12 domains incorporating constructs from psychological theories that focus on individual and environmental barriers and facilitators to effective implementation of evidence-based practice by health professionals. Results: The response rate was 32%. The 298 vaccinating GPs were positive about HPV vaccine implementation as part of their professional role as a worthwhile initiative within existing general practice infrastructure. They had more negative views about some aspects of program organisation, such as the timelines and potential adverse impacts on cervical screening rates. Vaccine safety was not a key concern. Actual levels of knowledge about HPV were moderate (mean score 3.41 out of 6 (s.d. 0.99)) and contrasted with self-rated knowledge, which was high (93% perceived their knowledge to be adequate). Notably, there were unrealistic expectations about the likely reduction in Pap abnormalities due to vaccination, which is important to clarify to avoid loss of confidence in the vaccine when this reduction does not eventuate. Conclusions: Australian GPs viewed HPV vaccination of women aged 18–26 years as an integrated part of their routine practice, with positive attitudes regarding its benefits and achievability. GPs are well placed to implement mass immunisation programs as long as they are supported by effective and timely communication strategies and resources.

scholarly journals School-based human papillomavirus vaccination program for increasing vaccine uptake in an underserved area in Texas

2019 ◽  
Vol 8 ◽  
pp. 100189 ◽  
Author(s):  
Sapna Kaul ◽  
Thuy Quynh N. Do ◽  
Enshuo Hsu ◽  
Kathleen M. Schmeler ◽  
Jane R. Montealegre ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Vaccine Uptake ◽  
Vaccination Program ◽  
Underserved Area ◽  
Human Papillomavirus Vaccination ◽  
School Based

scholarly journals Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects

2013 ◽  
Vol 275 (4) ◽  
pp. 398-408 ◽  
Author(s):  
L. Grimaldi-Bensouda ◽  
D. Guillemot ◽  
B. Godeau ◽  
J. Bénichou ◽  
C. Lebrun-Frenay ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Young Female ◽  
Autoimmune Disorders ◽  
Human Papillomavirus Vaccination ◽  
Female Subjects

scholarly journals A human papillomavirus vaccination program for low-income postpartum women

2016 ◽  
Vol 215 (3) ◽  
pp. 318.e1-318.e9 ◽  
Author(s):  
Abbey B. Berenson ◽  
Mahbubur Rahman ◽  
Jacqueline M. Hirth ◽  
Richard E. Rupp ◽  
Kwabena O. Sarpong
Keyword(s):  
Human Papillomavirus ◽  
Low Income ◽  
Vaccination Program ◽  
Postpartum Women ◽  
Human Papillomavirus Vaccination

scholarly journals Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan

Sexual Health ◽  
2015 ◽  
Vol 12 (6) ◽  
pp. 520 ◽  
Author(s):  
Luke B. Connelly ◽  
Ha N. D. Le
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Screening Program ◽  
Vaccine Coverage ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
The Cost

Background Human papillomavirus (HPV) vaccines and their widespread adoption have the potential to relieve a large part of the burden of cervical cancer morbidity and mortality, particularly in countries that have low screening rates or, like Japan, lack a cohesive universal screening program. An economic evaluation was conducted to assess the cost-effectiveness of introducing a bivalent HPV vaccination program in Japan from a healthcare perspective. Methods: A Markov model of the natural history of HPV infection that incorporates both vaccination and screening was developed for Japan. The modelled intervention, a bivalent HPV vaccine with a 100% lifetime vaccine efficacy and 80% vaccine coverage, given to a cohort of 12-year-old Japanese girls in conjunction with the current screening program, was compared with screening alone in terms of costs and effectiveness. A discount rate of 5% was applied to both costs and utilities where relevant. Results: Vaccination alongside screening compared with screening alone is associated with an incremental cost-effectiveness ratio (ICER) of US$20 315 per quality-adjusted-life-year gained if 80% coverage is assumed. The ICER at 5% coverage with the vaccine plus screening, compared with screening alone, is US$1158. Conclusion: The cost-effectiveness results suggest that the addition of a HPV vaccination program to Japan’s cervical cancer screening program is highly likely to prove a cost-effective way to reduce the burden of cervical cancer, precancerous lesions and HPV16/18-related diseases.

scholarly journals PIN68 Cost- Effectiveness Analysis of Human Papillomavirus Vaccination Program in Russia

2011 ◽  
Vol 14 (7) ◽  
pp. A277-A278
Author(s):  
V. Omelyanovsky ◽  
M. Avxentyeva ◽  
I. Krysanov ◽  
O. Ivakhnenko ◽  
S. Goryaynov ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
Effectiveness Analysis
Sign in / Sign up

Export Citation Format

Share Document